about
The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infectionInfant exposure to fine particulate matter and traffic and risk of hospitalization for RSV bronchiolitis in a region with lower ambient air pollutionNGF is an essential survival factor for bronchial epithelial cells during respiratory syncytial virus infection.Bronchiolar disorders.Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in miceCombination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice.The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P.Current treatment for acute viral bronchiolitis in infants.Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus.Assessment and management of children aged 1-59 months presenting with wheeze, fast breathing, and/or lower chest indrawing; results of a multicentre descriptive study in Pakistan.Human cathelicidin, LL-37, inhibits respiratory syncytial virus infection in polarized airway epithelial cells.Respiratory syncytial virus bronchiolitis.Low-fat yoghurt intake in pregnancy associated with increased child asthma and allergic rhinitis risk: a prospective cohort study.Affinity-purified respiratory syncytial virus antibodies from intravenous immunoglobulin exert potent antibody-dependent cellular cytotoxicity.Pretreatment with recombinant human vascular endothelial growth factor reduces virus replication and inflammation in a perinatal lamb model of respiratory syncytial virus infection.Recent advances in the management of acute bronchiolitis.Detection of human respiratory syncytial virus in respiratory samples by LightCycler reverse transcriptase PCR.A regional cohort study of the treatment of critically ill children with bronchiolitis.Risk factors for severe bronchiolitis caused by respiratory virus infections among Mexican children in an emergency department.Seven percent hypertonic saline--0.1% hyaluronic acid in infants with mild-to-moderate bronchiolitis.
P2860
Q26864494-E312F957-D00C-45BF-982B-FBA8376C0121Q28382905-C70283E8-9185-45B8-8D31-BB27826895A0Q33489541-F17AE108-5401-4555-A24E-23EBB4A4AEE7Q33844366-6196CAEE-45D7-41F7-AEA5-DE130A8E1D9AQ33920501-C4C9ED0D-1C1F-4251-8D65-1AD8014AA143Q34540179-1777E078-1B7E-4D30-81B1-38C372C346D2Q34996665-2A55581E-EA2C-4905-A7A3-23684FB9F7C2Q35183760-6F9303C2-8CB6-4435-BBDB-101971810852Q35222083-89392F3A-B3AC-4F3A-98BC-2335FAC35022Q35277675-E9677DE7-14C9-4DBE-836C-20D1868DBB9CQ35886054-41B0E01A-2B4B-4BE6-8854-4B46470527BAQ36361899-B9BF986A-9FF1-4FBB-A741-75FC76EECA5EQ36638478-BF9347F1-B967-490D-976A-A1AC624D0CBCQ37027756-D96E4463-585D-49FA-9F74-DB278A69F814Q37467898-06E9FA40-384D-49F0-BC54-9D84E9E2AA7AQ38314877-AD7FD894-89C6-4AC6-9F6A-36C74970D08FQ39751003-865932AC-34A3-4F66-91CA-5A0D4B11CD4DQ39768481-7B887FF5-0FE2-4544-9967-A7C640A4232DQ54265000-6A24C2A4-EF61-4CD6-BCDC-32BD60DB9756Q54296434-DA454EAE-30F2-4D84-9737-E73BEBDC0321
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Bronchiolitis in infants.
@ast
Bronchiolitis in infants.
@en
Bronchiolitis in infants.
@nl
type
label
Bronchiolitis in infants.
@ast
Bronchiolitis in infants.
@en
Bronchiolitis in infants.
@nl
prefLabel
Bronchiolitis in infants.
@ast
Bronchiolitis in infants.
@en
Bronchiolitis in infants.
@nl
P1476
Bronchiolitis in infants.
@en
P2093
Panitch HB
P304
P356
10.1097/00008480-200106000-00008
P577
2001-06-01T00:00:00Z